Literature DB >> 25197357

Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer.

Meng Zhang1, Feifei Cui2, Su Lu1, Huijun Lu1, Tao Jiang3, Jian Chen2, Xuemei Zhang1, Yubiao Jin1, Zhihai Peng2, Huamei Tang1.   

Abstract

Human prothymosin-α (PTMA) plays an important role in tumorigenesis, and its overexpression triggers a TP53 response. In this study, we identified that PTMA expression was up-regulated at both the transcriptional and translational level in tumor tissue compared to that in adjacent normal tissue. PTMA overexpression was significantly associated with the depth of tumor invasion, lymph node metastasis (LNM), distant metastasis, advanced AJCC stage, and tumor differentiation. There was also a significant association between PTMA over-expression and mutant TP53 expression (r=0.515, P < 0.001). Survival analysis revealed that the disease-free survival (DFS) and overall survival (OS) rates were significantly lower among patients with PTMA- and TP53-positive tumors. Hence, PTMA might play an important role in the progression of CRC, and the assessment of both PTMA and mutant TP53 expression can help predict colon cancer prognosis.

Entities:  

Keywords:  PTMA; TP53; biomarker; colorectal cancer; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25197357      PMCID: PMC4152047     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

1.  Expression of the prothymosin-a gene as a prognostic factor in lung cancer.

Authors:  H Sasaki; M Nonaka; Y Fujii; Y Yamakawa; I Fukai; M Kiriyama; M Sasaki
Journal:  Surg Today       Date:  2001       Impact factor: 2.549

2.  Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation.

Authors:  A Damalas; S Kahan; M Shtutman; A Ben-Ze'ev; M Oren
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

Review 3.  Decision making by p53: life, death and cancer.

Authors:  M Oren
Journal:  Cell Death Differ       Date:  2003-04       Impact factor: 15.828

4.  Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro.

Authors:  R S Orre; M A Cotter; C Subramanian; E S Robertson
Journal:  J Biol Chem       Date:  2000-10-17       Impact factor: 5.157

5.  Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa.

Authors:  Johanna D Strehl; Josef Hoegel; Ines Hornicek; Arndt Hartmann; Marc-Oliver Riener
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

6.  Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.

Authors:  A A Haritos; G J Goodall; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform.

Authors:  Mieko Shiwa; Yumiko Nishimura; Rumi Wakatabe; Ai Fukawa; Hisashi Arikuni; Hiroyuki Ota; Yo Kato; Takao Yamori
Journal:  Biochem Biophys Res Commun       Date:  2003-09-12       Impact factor: 3.575

8.  Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.

Authors:  Xuejun Jiang; Hyun-Eui Kim; Hongjun Shu; Yingming Zhao; Haichao Zhang; James Kofron; Jennifer Donnelly; Dave Burns; Shi-Chung Ng; Saul Rosenberg; Xiaodong Wang
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

9.  Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.

Authors:  Sandra Hapke; Horst Kessler; Birgit Luber; Anke Benge; Peter Hutzler; Heinz Höfler; Manfred Schmitt; Ute Reuning
Journal:  Biol Chem       Date:  2003-07       Impact factor: 3.915

10.  Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer.

Authors:  C Magdalena; F Dominguez; L Loidi; J L Puente
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  11 in total

1.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

Review 2.  Cell Senescence and Central Regulators of Immune Response.

Authors:  Sergey M Lunin; Elena G Novoselova; Olga V Glushkova; Svetlana B Parfenyuk; Tatyana V Novoselova; Maxim O Khrenov
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

3.  Prothymosin-α and parathymosin expression predicts poor prognosis in squamous and adenosquamous carcinomas of the gallbladder.

Authors:  Kang Chen; Li Xiong; Zhuling Yang; Shengfu Huang; Rong Zeng; Xiongying Miao
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

4.  Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.

Authors:  Anurag Kumar; Vikas Kumar; Mohit Arora; Manish Kumar; Prajwal Ammalli; Bhaskar Thakur; Jitender Prasad; Sarita Kumari; Mehar Chand Sharma; Shashank Sharad Kale; Shyam S Chauhan
Journal:  Biosci Rep       Date:  2022-04-29       Impact factor: 3.976

5.  Progression inference for somatic mutations in cancer.

Authors:  Leif E Peterson; Tatiana Kovyrshina
Journal:  Heliyon       Date:  2017-04-11

6.  "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

7.  Identification of prothymosin alpha (PTMA) as a biomarker for esophageal squamous cell carcinoma (ESCC) by label-free quantitative proteomics and Quantitative Dot Blot (QDB).

Authors:  Yanping Zhu; Xiaoying Qi; Cuicui Yu; Shoujun Yu; Chao Zhang; Yuan Zhang; Xiuxiu Liu; Yuxue Xu; Chunhua Yang; Wenguo Jiang; Geng Tian; Xuri Li; Jonas Bergquist; Jiandi Zhang; Lei Wang; Jia Mi
Journal:  Clin Proteomics       Date:  2019-04-05       Impact factor: 3.988

8.  A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors.

Authors:  Maowei Ni; Jie Zhou; Zhihui Zhu; Jingtao Yuan; Wangang Gong; Jianqing Zhu; Zhiguo Zheng; Huajun Zhao
Journal:  Front Cell Dev Biol       Date:  2021-08-30

9.  First Evidence of the Expression and Localization of Prothymosin α in Human Testis and Its Involvement in Testicular Cancers.

Authors:  Massimo Venditti; Davide Arcaniolo; Marco De Sio; Sergio Minucci
Journal:  Biomolecules       Date:  2022-08-31

Review 10.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.